[Recent therapeutics for Fabry disease].
Etou
Yoshikatsu
Y
D017485:1-Deoxynojirimycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064987:Cell- and Tissue-Based Therapy; D000795:Fabry Disease / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*; D015316:Genetic Therapy; D005944:Glucosamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007527:Isoenzymes / Q000627:therapeutic use; D008403:Mass Screening; D014281:Trihexosylceramides / Q000378:metabolism; D000519:alpha-Galactosidase / Q000235:genetics / Q000627:therapeutic use
D007527:Isoenzymes; D014281:Trihexosylceramides; C501633:deoxynojirimycine; D017485:1-Deoxynojirimycin; C018549:globotriaosylceramide; C059896:miglustat; D000519:alpha-Galactosidase; D005944:Glucosamine; C459420:agalsidase beta